Literature DB >> 804018

Pharmacokinetics of gentamicin sulfate in bronchial secretions.

J E Pennington, H Y Reynolds.   

Abstract

Dogs were used as a model for the study of the rate of appearance, peak concentrations, and rate of clearance of gentamicin sulfate in bronchial secretions. Gentamicin (dose, 1.7 mg/kg) was given by rapid intravenous infusion, by intramuscular injection, or as two divided intramuscular injections with a 4-hr interval. Intravenous infusion resulted in the highest bronchial concentrations of gentamicin, but the drug was cleared from the respiratory secretions in approximately 3 hr. In contrast, intramuscular injections gave low but more sustained bronchial leves of the drug. The time during which bronchial gentamicin concentrations exceeded a particular minimal inhibitory concentration for a susceptible bacterium such as Pseudomonas was related to the method of drug administration. Thus, to achieve the maximal antibiotic effectiveness, the minimal inhibitory concentraiton of gentamicin for the microorganism should be considered when the dose or frequency of parenteral gentamicin is prescribed.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 804018     DOI: 10.1093/infdis/131.2.158

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  4 in total

Review 1.  Nosocomial pneumonia in children.

Authors:  R F Jacobs
Journal:  Infection       Date:  1991 Mar-Apr       Impact factor: 3.553

Review 2.  Clinical pharmacokinetics of aminoglycoside antibiotics.

Authors:  J C Pechere; R Dugal
Journal:  Clin Pharmacokinet       Date:  1979 May-Jun       Impact factor: 6.447

3.  Anti-Pseudomonas activity in bronchial secretions of patients receiving amikacin or tobramycin as a continuous infusion.

Authors:  G Mombelli; L Coppens; J P Thys; J Klastersky
Journal:  Antimicrob Agents Chemother       Date:  1981-01       Impact factor: 5.191

4.  Pharmacological study of cefazolin during intermittent and continuous infusion: a crossover investigation in humans.

Authors:  J P Thys; B Vanderkelen; J Klastersky
Journal:  Antimicrob Agents Chemother       Date:  1976-09       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.